The Astrazenca plc announce an interim dividend declared of $0.93 (76.4 pence, 9.49 SEK) per ordinary share
Other financial highlights include:
‒ Total Revenue increased 48% to $22,161m, with growth coming from all disease areas and from the addition of Alexion
‒ Total Revenue from Oncology increased 22%, including receipt of a milestone payment. Product Sales from Oncology increased 18%. Total Revenue from R&I increased 3%, CVR increased 19% and Rare Disease increased 10%. Excluding a one-off historical pricing adjustment, Rare Disease increased 8%
‒ Core Gross Margin of 81%, with the second quarter benefitting from currency fluctuations, and phasing of COVID-19 medicine contracts
‒ Core Operating Margin of 33%. Core Total Operating Expense increased 33%, reflecting the addition of Alexion, and continued investment in new launches and the pipeline to build industry-leading mid-to-long term growth
‒ Core EPS of $3.61, with the second quarter benefitting from a Core Tax Rate of 15%. The FY 2022 expectation for the Core Tax Rate remains 18-22%
‒ FY 2022 Total Revenue guidance at CER increased due to an updated outlook for COVID-19 medicines and continued strong performance of the overall business, enabling further investment in the pipeline. With an expectation that Other Operating Income in H2 2022 will be similar to H1 2022, EPS guidance is unchanged
